Prot #STML-ELA-0322: ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)

Project: Research project

Project Details

StatusActive
Effective start/end date12/6/2412/6/27

Funding

  • Worldwide Clinical Trials, Inc. (Prot #STML-ELA-0322 // Prot #STML-ELA-0322)
  • Stemline Therapeutics, Inc. (Prot #STML-ELA-0322 // Prot #STML-ELA-0322)